Highland Private Wealth Management’s Neurogene NGNE Stock Holding History

Highland Private Wealth Management’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,350	Closed	-$30K	–	106
2022 Q3	$30K	Hold	2,350	–	–	﹤0.01%	182
2022 Q2	$48K	Hold	2,350	–	–	0.01%	186
2022 Q1	$88K	Hold	2,350	–	–	0.01%	186
2021 Q4	$227K	Hold	2,350	–	–	0.03%	170
2021 Q3	$340K	Hold	2,350	–	–	0.05%	122
2021 Q2	$434K	Hold	2,350	–	–	0.06%	102
2021 Q1	$579K	Hold	2,350	–	–	0.1%	78
2020 Q4	$663K	Buy	+2,350	New	+$574K	0.11%	66

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Highland Private Wealth Management's NGNE Position: Q4 2022 in Review

Highland Private Wealth Management sold out of Neurogene (NGNE) in Q4 2022, closing a stake of 2,350 shares — an estimated $30K sold.

Highland Private Wealth Management first reported a position in NGNE in Q4 2020 and held it in 8 quarters. The position peaked at $663K in Q4 2020. 44 funds tracked by Wall St. Rank hold NGNE as of Q4 2022.

Highland Private Wealth Management reported no remaining Neurogene position as of Q4 2022 after selling out during the quarter.
Highland Private Wealth Management sold 2,350 Neurogene shares in Q4 2022, an estimated $30K.
Highland Private Wealth Management first reported a position in Neurogene in Q4 2020 and held it in 8 quarters.
Highland Private Wealth Management's Neurogene position peaked at $663K in Q4 2020.
44 funds tracked by Wall St. Rank held Neurogene as of Q4 2022.

Based on Highland Private Wealth Management's 13F filing for Q4 2022.